Affimed (AFMD) News Today $1.19 +0.01 (+0.85%) (As of 12/20/2024 05:15 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Analyst revises Affimed Therapeutics stock price target amid AFM24 trial progressionDecember 20 at 11:43 PM | uk.investing.comAffimed (NASDAQ:AFMD) Receives $13.50 Consensus Target Price from BrokeragesDecember 20 at 1:41 AM | americanbankingnews.comAffimed price target lowered to $11 from $15 at Wells FargoDecember 19 at 1:04 AM | markets.businessinsider.comAffimed (AFMD) Gets a Buy from Truist FinancialDecember 19 at 1:04 AM | markets.businessinsider.comAffimed’s AFM24/atezolizumab combination shows positive results in NSCLC trialDecember 18 at 8:04 PM | markets.businessinsider.comAffimed price target lowered to $7 from $10 at H.C. WainwrightDecember 18 at 6:24 AM | tipranks.comAffimed’s Promising Clinical Update on NSCLC TreatmentDecember 18 at 4:36 AM | markets.businessinsider.comAffimed Shares Fall 32% on Clinical UpdateDecember 18 at 4:36 AM | finance.yahoo.comAffimed stock plunges 23% on AFM24 study updateDecember 18 at 4:36 AM | msn.comAffimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)December 17, 2024 | markets.businessinsider.comAffimed Reports Positive Data From AFM24-102 Trial In Heavily Pretreated NSCLC PatientsDecember 17, 2024 | markets.businessinsider.comAffimed (NASDAQ:AFMD) Price Target Cut to $15.00 by Analysts at Wells Fargo & CompanyDecember 15, 2024 | americanbankingnews.comShort Interest in Affimed (NASDAQ:AFMD) Decreases By 39.5%December 13, 2024 | americanbankingnews.comAffimed price target lowered to $15 from $20 at Wells FargoDecember 12, 2024 | tipranks.comAffimed's (AFMD) Buy Rating Reaffirmed at HC WainwrightDecember 11, 2024 | americanbankingnews.comAffimed reports ‘promising’ Phase 1 efficacy, safety data for AFM28December 9, 2024 | tipranks.comAffimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)December 9, 2024 | globenewswire.comAffimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung CancerDecember 9, 2024 | globenewswire.comAffimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) PatientsDecember 8, 2024 | globenewswire.comAffimed Announces RMAT Designation To Combination Therapy Of ICE Acimtamig And AB101December 5, 2024 | markets.businessinsider.comAffimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)December 5, 2024 | globenewswire.comIs Affimed N.V. (AFMD) the Best German Stock to Buy Now?November 19, 2024 | msn.comCantor Fitzgerald Reiterates "Overweight" Rating for Affimed (NASDAQ:AFMD)Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Affimed in a report on Tuesday.November 19, 2024 | marketbeat.comPromising Clinical Developments and Data Catalysts Position Affimed for Strong Future ProspectsNovember 17, 2024 | markets.businessinsider.comAffimed price target lowered to $4 from $5 at StifelNovember 17, 2024 | markets.businessinsider.comStifel Nicolaus Cuts Affimed (NASDAQ:AFMD) Price Target to $4.00Stifel Nicolaus cut their target price on Affimed from $5.00 to $4.00 and set a "hold" rating on the stock in a report on Friday.November 15, 2024 | marketbeat.comAffimed N.V. (NASDAQ:AFMD) Q3 2024 Earnings Call TranscriptNovember 15, 2024 | insidermonkey.comHC Wainwright Reiterates Buy Rating for Affimed (NASDAQ:AFMD)HC Wainwright reiterated a "buy" rating and set a $10.00 price objective on shares of Affimed in a report on Friday.November 15, 2024 | marketbeat.comAffimed Faces Growing Losses Amid Financial StrugglesNovember 15, 2024 | markets.businessinsider.comAffimed N.V. (AFMD) Q3 2024 Earnings Call TranscriptNovember 14, 2024 | seekingalpha.comAffimed Reports Third Quarter 2024 Financial Results & Business UpdateNovember 14, 2024 | globenewswire.comA Look Ahead: Affimed's Earnings ForecastNovember 13, 2024 | benzinga.comAffimed Q3 2024 Earnings PreviewNovember 13, 2024 | msn.comAffimed (AFMD) Set to Announce Earnings on ThursdayAffimed (NASDAQ:AFMD) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comAffimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024November 6, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Share Price Passes Above Fifty Day Moving Average - Time to Sell?Affimed (NASDAQ:AFMD) Stock Passes Above 50 Day Moving Average - Time to Sell?November 6, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Given Average Rating of "Buy" by AnalystsShares of Affimed (NASDAQ:AFMD - Get Free Report) have received a consensus rating of "Buy" from the four ratings firms that are presently covering the stock, MarketBeat reports. Four investment analysts have rated the stock with a buy recommendation. The average 12-month target price among analysOctober 28, 2024 | marketbeat.com683 Capital Management, LLC Expands Stake in Affimed NVOctober 24, 2024 | gurufocus.comAffimed (NASDAQ:AFMD) Given Average Rating of "Buy" by BrokeragesAffimed (NASDAQ:AFMD - Get Free Report) has earned a consensus rating of "Buy" from the four research firms that are currently covering the firm, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating. The average 12-month target price among brokerages that have issuOctober 3, 2024 | marketbeat.comTruist Financial Sticks to Its Buy Rating for Affimed (AFMD)September 24, 2024 | markets.businessinsider.comAffimed N.V. (A28A.F)September 11, 2024 | sg.finance.yahoo.comAffimed to Present at the Cantor Global Healthcare Conference 2024September 10, 2024 | globenewswire.comAffimed (NASDAQ:AFMD) Earns Overweight Rating from Cantor FitzgeraldCantor Fitzgerald reiterated an "overweight" rating on shares of Affimed in a report on Monday.September 9, 2024 | marketbeat.comAffimed (NASDAQ:AFMD) Receives Average Rating of "Buy" from AnalystsShares of Affimed (NASDAQ:AFMD - Get Free Report) have received a consensus recommendation of "Buy" from the four ratings firms that are covering the company, Marketbeat Ratings reports. Four analysts have rated the stock with a buy recommendation. The average 1 year target price among brokers thaSeptember 8, 2024 | marketbeat.comAffimed N.V. (NASDAQ:AFMD) Q2 2024 Earnings Call TranscriptSeptember 7, 2024 | msn.comBuy Rating Justified by Promising Clinical Data and Solid Progress in Affimed’s Drug DevelopmentsSeptember 6, 2024 | markets.businessinsider.comHC Wainwright Reiterates "Buy" Rating for Affimed (NASDAQ:AFMD)HC Wainwright reiterated a "buy" rating and set a $10.00 target price on shares of Affimed in a report on Friday.September 6, 2024 | marketbeat.comAffimed Reports Second Quarter 2024 Financial Results & Business UpdateSeptember 5, 2024 | markets.businessinsider.comAffimed N.V. (AFMD) Q2 2024 Earnings Call TranscriptSeptember 5, 2024 | seekingalpha.comAffimed Appoints Shawn M. Leland as Chief Executive OfficerSeptember 3, 2024 | globenewswire.com Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address URGENT: This Altcoin Opportunity Won’t Wait – Act Now (Ad)Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight. >> Register for the Workshop Now AFMD Media Mentions By Week AFMD Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AFMD News Sentiment▼0.420.61▲Average Medical News Sentiment AFMD News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AFMD Articles This Week▼142▲AFMD Articles Average Week Get Affimed News Delivered to You Automatically Sign up to receive the latest news and ratings for AFMD and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ENTA News Today ATOS News Today VXRT News Today CABA News Today PLX News Today IFRX News Today SAVA News Today APLT News Today ALGS News Today EDIT News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AFMD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Affimed Please log in to your account or sign up in order to add this asset to your watchlist. Share Affimed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AFMD Stock Alerts